NCIRE - The Veterans Health Research Institute Home  |  Sitemap  |  Intranet  |  UltiPro   Visit our Facebook page  Visit our Twitter page  Visit our LinkedIn page

Give Now
About NCIRE Participate in Research Support Our Mission Careers at NCIRE Contact Us
Veterans Health
Research at NCIRE

NCIRE-The Veterans Health Research Institute is the leading private nonprofit institute devoted to Veterans health research in the United States. Our mission is to advance Veterans health through research.

We support the work of some of the nation's foremost physicians and scientists at the San Francisco Veterans Affairs Medical Center, the premier biomedical research facility in the VA system. All have faculty appointments at the University of California, San Francisco, which has its own proud traditions of research and patient care. We also partner with the U.S. Department of Defense to support health research on behalf of our men and women in the Armed Forces.

Those who have served in uniform have given their best for their country. In return, we believe that they deserve nothing less than the best health care research we can provide.

Contact Us
Email NCIRE
Give Now
Lilly Y.W. Bourguignon, PhD

Career Scientist, Medical Service, SFVAHCS
Professor of Medicine, UCSF
Email: lilly.bourguignon@ucsf.edu

Cancer Cell Biology

Dr. Bourguignon is a cell biologist who has used a variety of biochemical, immunological and molecular biological techniques to elucidate the role of the protein CD44 in regulating the progression of human solid tumors, including breast cancer, ovarian cancer, prostate cancer, and head and neck squamous cell carcinoma. Her research studies also evaluate CD44 and various signaling molecules as markers for the propensity of solid tumors to spread; such markers would aid in assessing prognosis and diagnosis. Furthermore, she has developed several novel strategies to inhibit CD44-mediated signaling events and solid tumor progression. Her research could establish CD44 and associated signaling molecules as important tumor markers for early detection and evaluation of cancer, and could potentially allow the development of new drugs. Most importantly, the new information obtained from Dr. Bourguignon's cancer research program will have important clinical utility for the diagnosis, prognosis, and treatment of veteran patients, and therefore is highly relevant to the mission of SFVAMC.

To see Dr. Bourguignon on Pub Med, click here.